For all press and media enquiries please contact mediarelations@chiesi.com
Parma, Italy — November 21, 2016 — Chiesi Farmaceutici Spa (“Chiesi”), announced today that it has signed a definitive agreement for the acquisition of Atopix Therapeutics Limited, a UK clinical stage biotechnology company developing novel treatments for asthma. Under the terms of the agreement,…
Tuesday, November 8 -- The Italian Prime Minister Matteo Renzi, has today visited Chiesi Farmaceutici at the Research Center in Parma. The Prime Minister scheduled a meeting with Ugo di Francesco, Group CEO, Paolo Chiesi, Vice President, Alessandro Chiesi, Region Europe Director and Andrea Chiesi,…
Chiesi Farmaceutici SpA (Chiesi) announces today the submission to the European Medicines Agency (EMA) of the marketing authorisation application for the first ICS/LABA/LAMA triple combination. The product is indicated for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and is…
The Lancet publishes the results of Chiesi Farmaceutici TRILOGY study, which shows one year data on the superior efficacy of the first extrafine fixed ICS/LABA/LAMA triple combination for COPD treatment compared with standard therapy. The results of the study provide convincing support for the…
Chiesi is the first Company to complete 2 multicenter long-term clinical studies with an extrafine fixed triple combination for COPD The preliminary results of the two 12-month studies demonstrate that Chiesi extrafine fixed triple combination improves lung function, reduces exacerbations and…
In the treatment of chronic obstructive pulmonary disease (COPD) the combination of inhaled corticosteroids (ICS) and long acting bronchodilators LABA (Long Acting Beta2-agonists) reduces moderate and severe exacerbations, and it is recommended for this purpose in the in-force clinical guidelines. A…
Chiesi USA, Inc. and Chiesi Farmaceutici S.p.A., Chiesi USA's parent company, announced today that the companies have agreed to acquire worldwide rights of The Medicines Company to Kengreal® (cangrelor) and Cleviprex® (clevidipine), as well as rights to Argatroban for Injection, 50 mg per 50 mL. All…
Chiesi Farmaceutici generated just under €1.5bn in revenue in 2015, a year-on-year increase of almost 10%. The international footprint of the Group continues to grow: 80% of turnover is now from the non-Italian market. The expansion of Chiesi’s US affiliate is extremely promising, as is the Group’s…
The European Commission has granted a conditional marketing authorization, under Regulation (EC) No 726/2004, to Holoclar ®, an advanced therapy based on autologous stem cells and capable to restore the eyesight of patients with severe cornea damage. Holoclar ® is manufactured by Holostem Terapie…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
